MétaCan
Menu
Back to cohort
Record W4414919603 · doi:10.1016/j.rpth.2025.103201

Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage—a systematic review and meta-analysis

2025· review· en· W4414919603 on OpenAlexaff
Alexander Xiang, Sarah Lopes Sadafi, Rachael Principato, Asim Shaikh, Mehrad Nowrouzi, Ali Eshaghpour, Allen Li, Mark Crowther

Bibliographic record

VenueResearch and Practice in Thrombosis and Haemostasis · 2025
Typereview
Languageen
FieldMedicine
TopicAtrial Fibrillation Management and Outcomes
Canadian institutionsUniversity of GuelphUniversity of TorontoMcMaster University
FundersSyneos HealthBayerPfizerAmerican Society of Hematology
KeywordsStandard of careClinical trialRandomized controlled trialGold standard (test)MEDLINE

Abstract

fetched live from OpenAlex

Background Direct oral anticoagulants (DOACs) are activated factor X (FXa) or thrombin inhibitors. Patients on FXa inhibitors are at increased risk for major bleeding events that require anticoagulation reversal. Andexanet alfa is a FXa inhibitor reversal agent, potentially offering better efficacy compared to standard of care options. Objectives To conduct a systematic review and meta-analysis comparing the efficacy and safety of Andexanet alfa versus standard of care for reversing FXa inhibitorinduced ICH. Methods Random-effects meta-analysis. Ovid Medline, EMBASE, and CINAHL were searched from inception until February 1 st , 2025. Primary outcomes included hemostatic efficacy, thrombotic events, and mortality. Subgroup analyses isolated studies using 4F-PCC as standard-of-care and ANNEXA-4 definitions of hemostatic efficacy. Results 3039 studies were identified, with 23 studies (1 RCT, 452 participants; 22 nonrandomized, 4085 participants) included in the final analysis. Thirteen studies assessed hemostatic efficacy, with a pooled odds ratio of 1.68 (95%CI 1.20-2.36, p=0.003, I 2 =0%) favoring Andexanet over standard of care. Thirteen studies reported thrombotic events, with a pooled odds ratio of 0.97 (95%CI 0.59-1.60, p=0.90, I 2 =0%). Thirteen studies assessed mortality, noted a pooled OR of 0.69 (95%CI 0.50-0.96, p=0.03, I 2 =27%) favoring the Andexanet group. Published RCTs showed similar hemostatic improvements but no mortality benefit and a higher rate of thrombotic events. Conclusions Our meta-analysis found low-certainty evidence supporting improved hemostatic efficacy with Andexanet alfa compared to standard-of-care, with a decrease in mortality and no effect on thrombotic complications. Further randomized data is required to establish a conclusive clinical benefit favoring Andexanet alfa.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.023
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.019
Threshold uncertainty score0.058

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0110.023
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0190.042
Bibliometrics0.0050.006
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.413
GPT teacher head0.540
Teacher spread0.126 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueResearch and Practice in Thrombosis and HaemostasisSame topicAtrial Fibrillation Management and OutcomesFrench-language works237,207